ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301

Its studies are led by Day One Biopharmaceuticals.

Furthest: phase 1, since Dec 23, 20241 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Day One Biopharmaceuticals11 open or runningphase 1since Dec 23, 2024Dec 23, 2024Dec 2027phase 1 · NCT06752681

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 23, 2024First study: phase 1 study in Advanced or Metastatic Solid TumorsFirst studyNCT06752681 · 300 planned · United States, Canada

Ahead

  1. Dec 2027Primary completion: phase 1 study in Advanced or Metastatic Solid TumorsNCT06752681

TargetBeta

PTK7 →read by rule
“An antibody-drug conjugate (ADC) composed of Ab13, an antibody directed against human inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) ”NCIt, by rule

Other programs on PTK7

ProgramCompanyFurthest phaseStudies
Anti-PTK7 Antibody-drug Conjugate SKB518ruleSichuan Kelun Pharmaceuticalphase 23
Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408ruleEli Lillyphase 11
Anti-PTK7 Antibody-drug Conjugate HWK-007rulewhitehawk-therapeutics-incphase 11
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06752681Advanced or Metastatic Solid Tumors · United States, Canada1RecruitingDec 2027300

How it is read

Names in the registry

  • “DAY301”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.